Rosuvastatin Calcium Tablets from the 6-Acetoxymethyl Dioxane Precursor

In the synthesis of rosuvastatin calcium, tert-butyl (4R,6S)-6-(acetoxymethyl)-2,2-dimethyl-1,3-dioxane-4-acetate (CAS 154026-95-6) functions as the protected C7 side-chain building block that is first converted to the hydroxymethyl derivative and then to the formyl intermediate before the pyrimidine ring is introduced. The downstream process at pilot scale typically begins by dissolving the acetyl-protected intermediate in methanol at a concentration of 0.8–1.2 mol/L, cooling the solution to 0–5 °C, and charging methanolic sodium methoxide at 0.02–0.05 molar equivalents relative to the dioxane acetate; this addition ratio is maintained below the threshold that causes detectable acetonide ring opening, and the reaction is quenched with acetic acid after 2–4 h. The resulting hydroxymethyl intermediate is solvent-swapped into dichloromethane and oxidized with 0.01–0.03 molar equivalents of TEMPO and 1.05–1.20 molar equivalents of aqueous sodium hypochlorite at 0–5 °C, producing tert-butyl (4R,6S)-6-formyl-2,2-dimethyl-1,3-dioxane-4-acetate. The formyl intermediate is then coupled in anhydrous tetrahydrofuran with the rosuvastatin pyrimidine-derived phosphonium salt at −20 to −10 °C using potassium tert-butoxide at 1.00–1.10 molar equivalents; after coupling, the acetonide and tert-butyl ester protecting groups are removed under methanolic hydrogen chloride, and the calcium salt is precipitated from water/acetone. The terminal dosage forms produced from this route are rosuvastatin calcium film-coated tablets in strengths of 5 mg, 10 mg, 20 mg, and 40 mg, with compliance against the USP Rosuvastatin Calcium Tablets monograph, dissolution testing under USP 711, and residual solvent control under ICH Q3C. The (4R,6S) configuration is controlled through the entire sequence by chiral HPLC, and the residual acetoxymethyl intermediate in the isolated rosuvastatin calcium API is typically specified at ≤0.10% HPLC area percentage before formulation.

How Does Residual Acetyl Protection Influence Chiral Purity in Rosuvastatin Side-Chain Elaboration?

A critical quality attribute in the deacetylation sequence is the retention of the (4R,6S) configuration while the acetoxymethyl protecting group is removed, because the dioxane ring masks the 3,5-diol functionality that becomes the pharmacophore after final deprotection. In-process chiral purity is monitored on a polysaccharide-based chiral column, typically Chiralpak AD-H 250 mm × 4.6 mm, 5 µm, using an n-hexane/ethanol 90:10 mobile phase at 1.0 mL/min; the undesired (4S,6R) antipode is quantified at an area-percentage limit of ≤0.10%. The release of the hydroxymethyl intermediate from the acetate is performed with methanolic sodium methoxide at 0.02–0.05 molar equivalents relative to the protected dioxane acetate; when the base charge exceeds 0.10 molar equivalents or the reaction temperature rises above 10 °C, LC-MS data show formation of the open-chain triol impurity resulting from acetonide hydrolysis, which can reduce downstream coupling efficiency and complicate crystallization of rosuvastatin calcium. The downstream process is executed in a glass-lined reactor with retreat-curve impeller agitation at 80–120 rpm, maintaining the temperature at 0–5 °C through jacket cooling with −10 °C brine; after aqueous quench, the dichloromethane layer is washed with 5 wt% sodium bicarbonate and dried over anhydrous sodium sulfate before vacuum solvent exchange. The terminal finished product remains rosuvastatin calcium film-coated tablets, and the process controls align with ICH Q6A, ICH Q7, and Ph. Eur. chapter 2.2.46 for liquid chromatography. The chloride content of the methanolic HCl used in the final deprotection step is kept at 1.0–1.2 molar equivalents relative to the tert-butyl ester, and this addition ratio prevents residual tert-butyl ester from persisting into the calcium salt.

Generic atorvastatin calcium API manufacturers have evaluated the same (4R,6S)-6-(acetoxymethyl)-2,2-dimethyl-1,3-dioxane-4-acetic acid tert-butyl ester as a side-chain precursor because the acetyl-protected alcohol can be converted to the formyl intermediate and then coupled to a pyrrole-derived phosphonate in a Horner-Wadsworth-Emmons sequence, followed by hydrogenation of the resulting double bond to the ethyl-linked atorvastatin side chain. The molar addition ratio commonly used in this downstream sequence is 1.00 mol of the dioxane formyl intermediate per 1.05–1.10 mol of the atorvastatin pyrrole methyl phosphonate, with 1.10–1.20 molar equivalents of sodium hydride or potassium tert-butoxide as the base in anhydrous tetrahydrofuran at −10 to 0 °C. After coupling and hydrogenation over a palladium catalyst, the acetonide and tert-butyl ester groups are removed under acidic conditions, and atorvastatin calcium is crystallized from aqueous acetonitrile before drying under vacuum at 40–50 °C. The terminal dosage form produced from this route is atorvastatin calcium film-coated tablets in strengths of 10 mg, 20 mg, 40 mg, and 80 mg, with compliance against the USP Atorvastatin Calcium Tablets monograph and residual solvent limits under ICH Q3C. Residual acetoxymethyl intermediate in the final atorvastatin calcium API is controlled at ≤0.10% HPLC area percentage, consistent with ICH Q3A identification thresholds for a maximum daily dose of 80 mg; this control is necessary because the protected intermediate is not present in the finished tablet but may be detected as a process-related impurity during regulatory review.

When a European DMF/ASMF Submission Requires a Residual Solvent Compliance Matrix

For manufacturers filing a European ASMF or US DMF for statin APIs derived from this intermediate, the residual solvent profile of the isolated tert-butyl (4R,6S)-6-(acetoxymethyl)-2,2-dimethyl-1,3-dioxane-4-acetate must be reported against the limits of ICH Q3C, Ph. Eur. chapter 5.4, and USP 467. The downstream process for this intermediate typically includes dichloromethane as the reaction solvent, ethyl acetate as the extraction solvent, and acetone as the crystallization solvent; the corresponding residual solvent acceptance limits are 600 ppm for dichloromethane as a Class 2 solvent, 5000 ppm for acetone, and 5000 ppm for ethyl acetate as Class 3 solvents. The addition ratio of the recrystallization solvent system in which the isolated intermediate is purified is 3–5 volumes of n-heptane to 1 volume of ethyl acetate at −10 to 0 °C, and the isolated solid is dried in a vacuum tray dryer at 35–40 °C for 8–12 h. The downstream process includes headspace gas chromatography with flame ionization detection, using a split injection ratio of 1:20, a dimethylformamide diluent, and an equilibration temperature of 80 °C for 30 min, with calibration solutions prepared from 0.1× to 2.0× the ICH Q3C limit. The terminal finished product types covered by this compliance matrix are rosuvastatin calcium film-coated tablets, atorvastatin calcium film-coated tablets, and pitavastatin calcium tablets; injectable dosage forms are not part of the commercial downstream portfolio for this intermediate, because no approved parenteral statin product is established under current EMA or FDA monographs.

Pitavastatin calcium process development for the Japanese and European markets can draw on the same protected C7 dioxane acetate because the corresponding formyl intermediate is structurally suitable for Wittig coupling to a 2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl phosphonium salt; however, published data for this specific configuration in quinoline-containing statin routes is limited, and the process is typically evaluated by generic API manufacturers under non-infringing route scouting rather than as a standard commercial source. The downstream process involves release of the hydroxymethyl intermediate, oxidation to the formyl derivative, and Wittig coupling in anhydrous tetrahydrofuran with 1.00 mol of the formyl intermediate per 1.05–1.10 mol of the quinolyl phosphonium salt at −20 to −10 °C, using potassium tert-butoxide at 1.00–1.10 molar equivalents relative to the phosphonium salt. After formation of the protected heptenoic acid side chain, the acetonide and tert-butyl ester protecting groups are cleaved under acidic conditions, and pitavastatin calcium is crystallized from aqueous acetonitrile before drying. The terminal finished product types are pitavastatin calcium film-coated tablets in strengths of 1 mg, 2 mg, and 4 mg, with compliance against the Japanese Pharmacopoeia and Ph. Eur. monograph requirements for pitavastatin calcium. Residual acetoxymethyl intermediate in the isolated pitavastatin calcium API should be controlled at ≤0.10% HPLC area percentage, and the absence of mutagenic acrylate or sulfonate impurities in the side chain is supported by purge factors calculated under ICH M7. The final oral tablets are the only commercial terminal product type; injectable formulations of pitavastatin are not marketed.

Evaluating Solvent and Containment Boundaries in Pilot-Plant Scale-Up

At the pilot-plant scale, the acetylation of tert-butyl (4R,6S)-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxane-4-acetate with acetic anhydride is executed in a 500 L glass-lined reactor with a retreat-curve impeller at 80–120 rpm, and the addition ratio of acetic anhydride is set at 1.15–1.30 molar equivalents relative to the hydroxymethyl precursor to compensate for trace moisture in the dichloromethane feed. The reactor is maintained at 0–5 °C during the 45–60 min addition, and the jacket is charged with −10 °C brine because the reaction exotherm can raise the batch temperature by 15–25 °C if the addition is completed too rapidly; this thermal boundary is a critical processing window for maintaining the acetonide ring and avoiding acetyl migration. After quench with 5 wt% aqueous ammonium chloride, the organic layer is washed with 5 wt% sodium bicarbonate and 10 wt% sodium chloride, dried over anhydrous magnesium sulfate, and concentrated in a wiped-film evaporator at 40–50 °C under 150–250 mbar. The isolated intermediate is then recrystallized from n-heptane/ethyl acetate 3:1 to 5:1 at −10 to 0 °C and dried in a vacuum tray dryer at 35–40 °C for 8–12 h, with the residual dichloromethane and ethyl acetate contents verified by HS-GC before release. The commercial terminal product types arising from this intermediate are oral rosuvastatin calcium, atorvastatin calcium, and pitavastatin calcium film-coated tablets; no approved injectable statin dosage form exists, so the material is not released against parenteral-grade endotoxin or particulate limits unless a specific customer qualification protocol for an investigational parenteral formulation is established. The process is conducted under ICH Q7 Section 5.3 for equipment cleaning, 21 CFR 211.42 for facility design, and 21 CFR 211.67 for equipment maintenance.